Pfizer Inc. (PFE) Q3 2026 (USD): Adj. EPS 0.87 (exp. 0.73), Revenue 16.6bln (exp. 15.85bln), Current FY EPS 2.95-3.05 (exp. 2.96), Current FY Rev. 62-64bln (exp. 62.24bln)

Pfizer Inc. (PFE) Q3 2026 (USD): Adj. EPS 0.87 (exp. 0.73), Revenue 16.6bln (exp. 15.85bln), Current FY EPS 2.95-3.05 (exp. 2.96), Current FY Rev. 62-64bln (exp. 62.24bln)

A double beat on adjusted EPS and revenue with the full-year outlook framed at or above consensus is the classic pattern for a large-cap pharma name whose equity story has been one of post-pandemic revenue decline, where the bar is typically set low and beats are the norm rather than the exception. In past episodes of this kind for Pfizer specifically, the sustainability of the reaction has hinged less on the headline numbers than on the composition of the beat: COVID franchise revenue is volatile and discounted heavily, so beats driven there have tended to fade faster than beats driven by the core oncology and non-COVID portfolio. The guidance raise here, moving the EPS midpoint above prior consensus, matters more than the quarter itself, since repeated guidance nudges have historically been the mechanism by which this stock rebuilds credibility after a long derating. What follows the print is the call, where the tells are the split between COVID and non-COVID growth, pipeline readouts on the obesity and oncology programmes, and any commentary on cost discipline and capital allocation, which has included substantial deal activity funded from the balance sheet. Reaction in the peer set is usually limited; this trades on company-specific execution rather than sector read-across. The distinction worth drawing is between a beat that raises the durable earnings base and one that merely pulls forward revenue, and the call is where that gets resolved.